Keros Therapeutics, Inc. (NASDAQ: KROS ) got slammed last week after it halted two higher dosage arms of a Phase 2 TROPOS trial of its drug cibotercept in patients with pulmonary arterial hypertension, or PAH, over safety concerns. Fellow SeekingI am a private investor based out of Toronto, Canada and I have been investing since 2003. After 8 years in Corporate Finance with a Canadian Telecom company I have decided to dedicate myself full-time to the capital markets. I write on Seeking Alpha to demonstrate ...